Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Conference News AHA 2016

Incomplete Revascularization Linked With Increased MACE in Subsequent Noncardiac Surgery

Michael O'Riordan

November 15, 2016

News Daily News

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Yael L. Maxwell

September 26, 2016

News Daily News

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

Yael L. Maxwell

September 14, 2016

News Daily News

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Yael L. Maxwell

June 15, 2016

News Daily News

Most Patients Undergoing Diagnostic Angiography Before Noncardiac Surgery Are Asymptomatic

Michael O'Riordan

March 31, 2016

News Daily News

Novel Oral Anticoagulant for VTE Prevention Misses Primary Endpoint in APEX

Todd Neale

March 24, 2016

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

Meta-analysis Shows Watchman Still Noninferior to Warfarin, With Good Safety Outcomes

Yael L. Maxwell

June 17, 2015

Presentation VEINS 2014

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Presenter: James B. Froehlich

October 10, 2014

News Daily News

HORIZONS-AMI Substudy: Anticoagulation After Primary PCI Yields Worse Outcomes

September 02, 2014

News Daily News

Cardiac Cath via Radial Access Safe, Effective for Liver Transplant Patients

Jason Kahn

March 14, 2014

News Daily News

Meta-analysis: Vena Cava Filters Safe, Effective in Reducing Pulmonary Embolism

March 05, 2014

News Daily News

Percutaneous Mitral Commissurotomy Effective Even in Calcified Valves

January 15, 2014

News Daily News

Fever After TAVR Common, but Antibiotics Rarely Needed

L.A. McKeown

January 15, 2014

Presentation VEINS 2013

Current Recommendations for VTE Risk Assessment and In-Hospital Prophylaxis

Presenter: Teresa L. Carman

September 21, 2013

News Daily News

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

Yael L. Maxwell

May 17, 2013

News Daily News

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

Yael L. Maxwell

May 17, 2013

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

Advertisement

Incomplete Revascularization Linked With Increased MACE in Subsequent Noncardiac Surgery

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Most Patients Undergoing Diagnostic Angiography Before Noncardiac Surgery Are Asymptomatic

Novel Oral Anticoagulant for VTE Prevention Misses Primary Endpoint in APEX

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Meta-analysis Shows Watchman Still Noninferior to Warfarin, With Good Safety Outcomes

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

HORIZONS-AMI Substudy: Anticoagulation After Primary PCI Yields Worse Outcomes

Cardiac Cath via Radial Access Safe, Effective for Liver Transplant Patients

Meta-analysis: Vena Cava Filters Safe, Effective in Reducing Pulmonary Embolism

Percutaneous Mitral Commissurotomy Effective Even in Calcified Valves

Fever After TAVR Common, but Antibiotics Rarely Needed

Current Recommendations for VTE Risk Assessment and In-Hospital Prophylaxis

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content